Simply Wall Street has concerns
"Noxopharm has a market capitalisation of AU$37m and burnt through AU$14m last year, which is 38% of the company's market value. That's not insignificant, and if the company had to sell enough shares to fund another year's growth at the current share price, you'd likely witness fairly costly dilution.
How Risky Is Noxopharm's Cash Burn Situation?
On this analysis of Noxopharm's cash burn, we think its cash runway was reassuring, while its cash burn relative to its market cap has us a bit worried.
Summing up, we think the Noxopharm's cash burn is a risk, based on the factors we mentioned ie revenue and cash burn rate.
BTW no Director trades have been undertaken for some time eg on-market.
The SP has taken a hammering.
Thoughts on viability?
Add to My Watchlist
What is My Watchlist?
